HDAC Inhibitors Are Class Drugs That Restrict The Growth Of Tumor Cells
![]() |
| HDAC Inhibitors |
HDAC Inhibitors are a new class of
anti-cancer agents that have recently been shown to induce apoptosis and cell
cycle arrest in cancer cells. Several of these drugs are currently in clinical
trials for the treatment of a variety of cancers, and some are also being
investigated as possible treatment options for a range of other diseases. These
include inflammatory and muscular dystrophies as well as autoimmune disorders.
The
anti-cancer activity of HDAC
Inhibitors is largely dependent on their ability to inhibit epigenetic
changes. Thus, they should be used in combination with other agents to maximize
their anti-cancer efficacy and safety.
Inhibitors
of HDACs can be divided into three major groups: hydroxamic acid-based pan-HDAC
inhibitors, aliphatic acids, and cyclic peptides. Inhibitors of HDACs that are
selective to classes I and II are commonly referred to as cyclic peptides,
while inhibitors of HDACs that are class III are known as aliphatic acids.
The
most common class of HDAC Inhibitors
is the hydroxamic acid-based group that includes suberoylanilide hydroxamic
acid (SAHA/Vorinostat/Zolinza), trichostatin A (TSA), and PXD-101, all of which
can inhibit HDACs in a cytosolic as well as a nuclear fashion. Some of these
compounds, including SAHA and TSA, are currently in clinical development for
cancer treatment, and others, such as MS-275 and MGCD0103, are in preclinical
testing.
HDAC Inhibitors are based on a ring
system, in which a methyl group, usually a sulfydryl group, is linked to a
zinc-containing active site pocket. These molecules inhibit class I and II
HDACs selectively in cell-free assays.
They have very low toxicity and are well tolerated, but they have limited clinical efficacy in treating a variety of different cancers. Because of the wide range of tumor types and the complex pathways that govern their response to HDAC inhibition, a broader understanding of these drugs' mechanism of action is needed to determine their effectiveness in treating other diseases

Comments
Post a Comment